HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (16)
  • Publications (14)
  • References (21)
  • Uncategorized (6)

Recent Posts

April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio
April 7, 2025

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

by PJWCreative
January 13, 2025

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

by PJWCreative
December 18, 2024

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

by PJWCreative
Post placeholder image
September 18, 2024

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 16, 2024

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
September 3, 2020 in Publications

When liposomes met antibodies: Drug delivery and beyond

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
June 24, 2020 in References

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
March 2, 2020 in Publications

Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging

PJWCreative 0 Like Post Comments Off on Asian Journal of Pharmaceutical Sciences: Oral Uptake and Persistence of the FnAb-8 Protein Characterized by In Situ Radio-labeling and PET/CT Imaging
Read More
Post placeholder image
September 28, 2019 in References

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
November 30, 2018 in References

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
November 2, 2018 in Publications

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
October 26, 2018 in References

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
July 1, 2018 in Publications

Molecular Cancer Therapeutics: Selective Targeting and Eradication of LGR5+ Cancer Stem Cells Using RSPO-Conjugated Doxorubicin Liposomes

PJWCreative 0 Like Post Comments Off on Molecular Cancer Therapeutics: Selective Targeting and Eradication of LGR5+ Cancer Stem Cells Using RSPO-Conjugated Doxorubicin Liposomes
Read More
Post placeholder image
December 28, 2016 in References

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
March 15, 2016 in References

Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo

PJWCreative 0 Like Post 0 Comment
Read More
Prev1…3456Next

Download Company Profile

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin
HIGHfield_logo_horizontal_FINAL_trans

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

HIGHFIELD_web_LI_icon_x75

© 2024 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文